Trials / Unknown
UnknownNCT03983928
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Subjects With Advanced Mutation Positive Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. |
| DRUG | Anlotinib | a multi-target receptor tyrosine kinase inhibitor |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2020-10-31
- Completion
- 2020-12-31
- First posted
- 2019-06-12
- Last updated
- 2019-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03983928. Inclusion in this directory is not an endorsement.